NASDAQ: SPRY neffy – the transformative needle -free solution for severe allergic reactions March 2026 Corporate Presentation Forward-looking statements Statements in this presentation that are not purely historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this presentation include, without limitation, statements regarding: the potential market, demand and expansion opportunities for neffy; the belief ...

Investor Overview CONFIDENTIAL ©NETSOL TECHNOLOGIES, INC Why NETSOL Technologies NETSOL is a provider of AI-enabled solutions and services powering OEMs, dealerships and financial institutions to sell, finance and lease assets. Americas 40+ Years Austin I Los Angeles Europe & UK 30+ Years Horsham I London APAC 25+ Years Beijing I Jakarta I Lahore Bangkok I Sydney I Tianjin I Shanghai Proven globally Fortune 500 Dozens of companies served 200+ Global clients 300+ Successful implementations 100+ Automotive pr ...

Non-Viral Genetic Medicine Corporate Presentation Disclaimers Cautionary Statement Regarding Forward-Looking Statements The lead program described herein is an investigational drug therapy that has not been subject to testing designed to demonstrate that the therapy is effective in humans or to provide a basis to predict in advance whether an adequate level of efficacy in humans will be demonstrated in further testing. Although deemed sufficient to permit further testing, the limited, early Phase 1 testing ...

Investor Presentation March 2026 NASDAQ: LFMD Important Cautions Regarding Forward-Looking Statements This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this presentation may be identified by the use of words such as: "believe," "expect ...

Forward Looking Statements This presentation and other communications by the Bank and its management may include certain statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the fact that they do not relate strictly to historical or current facts. Forward-looking statements often use words such as "anticipates," "targets," "expects," "hopes," "estimates," "intends," "plans," "goals," "believe ...

Unlocking a New Paradigm in Cancer Treatment via ecDNA-Directed Therapies (ecDTx) Corporate Presentation March 2026 Nasdaq: BOLD @BoundlessBio Disclaimer: Forward-Looking Statements and Market Data We caution you that this presentation contains forward-looking statements about us and our industry. All statements other than statements of historical facts contained in this presentation are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors t ...

March 9, 2026 Legal Notices The information in this slide deck is current as of March 9, 2026, unless otherwise noted, and is qualified in its entirety by reference to MacroGenics' Annual, Quarterly and Current Reports filed with the SEC. MacroGenics undertakes no obligation to update any of the information herein. Cautionary Note on Forward-Looking Statements Any statements in this presentation about future expectations, plans and prospects for MacroGenics ("Company"), including statements about the Compan ...

Corporate Presentation March 2026 Confidential Forward Looking Statements & Disclaimers This presentation contains "forward-looking" statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated discovery, preclinical and clinical development activities for Prelude's product candidates and milestones, the potential safety, efficacy, benefits and addressable market for Prelude Therapeutic Incorporated's (the " ...

BREAKTHROUGH ANTIBODIES FOR OBESITY AND CARDIOMETABOLIC DISEASES CORPORATE PRESENTATION March 2026 Forward looking statements Certain statements in this presentation constitute "forward -looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 , as amended. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, be ...

Lonza Completes its Transformation to a Pure -Play CDMO with Agreement to Divest Capsules & Health Ingredients Dr. Wolfgang Wienand – Chief Executive Officer Philippe Deecke – Chief Financial Officer 6 March 2026 Disclaimer Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange . It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX -ST") . Lonza Group Ltd is not subject to the SGX -ST's continuing listing requirements but remains ...